TABLE 3.

Pretransarterial chemoembolization features associated with mortality according to Cox regression analysis in patients with hepatocellular carcinoma

	Mortality (n=31)	Alive (n=29)	HR	95% CI	P
Features associated in the univariate analysis
Age at diagnosis, years	61±2	58±2	0.41	0.98–1.04	0.4
Men:women, n:n	26:5	24:5	1.26	0.48–3.29	0.6
Viral hepatitis (B and C), n (%)	13 (42)	20 (69)	0.33	0.34–1.44	0.3
Alanine aminotransferase (normal <50 U/L)	80±14	79±11	0.99	0.99–1.003	0.4
Aspartate aminotransferase (normal <38 U/L)	95±14	93±12	1.00	0.99–1.006	0.9
Alkaline phosphatase (normal 30–130 U/L)	150±14	143±24	1.002	0.99–1.006	0.5
Bilirubin (normal <20 μmol/L)	23±3	24±3	1.02	0.99–1.05	0.1
International normalized ratio (normal 0.8–1.2)	1.2±0.02	1.2±0.08	0.58	0.17–1.93	0.4
Albumin (normal 35–50 g/L)	37±1	35±1	0.98	0.92–1.04	0.5
Creatinine (normal <125 mol/L)	89±5	76±3	1.01	0.99–1.03	0.08
Alpha-fetoprotein (normal <10 ng/mL)	3891±3315	925±626	1.01	1.00–1.02	0.03
Alpha fetoprotein >200 ng/mL	14 (45)	5 (17)	2.35	1.14–4.87	0.02
Model for End-stage Liver Disease score	8.9±0.6	8.2±0.6	1.11	0.98–1.26	0.09
Model for End-stage Liver Disease score >10, n (%)	10 (32)	5 (17)	4.19	1.79–9.78	0.001
Child-Turcotte-Pugh class, A:B, n	19:12	20:9	0.69	0.34–1.44	0.3
BCLC, A:B:C, n	2:26:3	8:20:1	2.58	0.95–7.03	0.06
Tumours, n	2.0±0.3	2.2±0.4	1.04	0.83–1.31	0.7
Total tumour size (1D), cm	7.9±0.9	5.6±0.7	1.07	0.98–1.16	0.1
Total tumour size (2D), cm2	63±13	38±10	1.005	0.99–1.011	0.08
Total tumour size (3D), cm3	381±115	194±76	1.001	1.00–1.001	0.06
Features associated in the multivariate analysis
Alpha-fetoprotein (normal <10 ng/mL)	3891±3315	925±626	1.01	1.00–1.02	0.008
Model for End-stage Liver Disease score >10, n (%)	10 (32)	5 (17)	4.55	1.92–10.78	0.001

Data presented as mean ± SEM unless otherwise indicated. 1D One dimension; 2D Two dimensions; 3D Three dimensions; BCLC Barcelona Clinic Liver Cancer staging classification